Consistent with preclinical and clinical studies, we found that targeting PD‐L1 alone was not effective in reducing tumor burden, whereas CD47 treatment sensitized the tumor to the immune system and significantly reduced tumor growth. The gene discussed is CD47; the disease is neoplasm.